March 28, 2019
Astellas Pharma’s investigational postmenopausal vasomotor symptoms (VMS) treatment fezolinetant (development code: ESN364) met the four US FDA-recommended endpoints in a PIIb clinical study in the US, the company said on March 27. Fezolinetant, a selective neurokinin-3 (NK3) receptor antagonist, works...read more